Nathan Fowler

18.2k citations

267 papers · 5.8k indexed · 2 hit papers · h-index 34

Impact in

Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 125
- Chronic Lymphocytic Leukemia Research 121
Pathology and Forensic Medicine 191
- Lymphoma Diagnosis and Treatment 191

Co-authors: Chan Y. Cheah John G. Gribben Luis Fayad Thomas E. Boyd Franck Morschhauser Sonali M. Smith Sattva S. Neelapu Ranjana H. Advani
Journals: Blood (78 papers)Journal of Clinical Oncology (54 papers)British Journal of Haematology (15 papers)Hematological Oncology (12 papers)Annals of Oncology (7 papers)
Partner nations: United States Australia France

In The Last Decade

Nathan Fowler

246 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy 2021 · 700 citations

Peers

Countries citing papers authored by Nathan Fowler

Since Specialization

Citations

This map shows the geographic impact of Nathan Fowler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Fowler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Fowler more than expected).

Fields of papers citing papers by Nathan Fowler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Fowler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Fowler. The network helps show where Nathan Fowler may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nathan Fowler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nathan Fowler Line = papers co-authored together Nathan Fowler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making. Journal of Clinical Oncology ·Kevin R. Criswell, Anastasia A. Makarova, Alexandra Maritza Fernandez Mendieta, Kirill Kryukov, Jovianto Jovianto, Eric Ball, T Malathi, Innasa Permata Triaswidadi, Hanafi Hadi Susanto, Ya. R. Maksymenko, Nathan Fowler, J. W. Landon, Jason S. Starr, Jeffrey Clarke	2024	0
2	IMMUNE‐DEPLETED TUMOR MICROENVIRONMENT IS ASSOCIATED WITH POOR OUTCOMES AND BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMA Hematological Oncology ·Preetesh Jain, Krystle Nomie, Nikita Kotlov, Holly A. Hill, Chi Young Ok, Yohana Yohana, Rashmi Kanagal‐Shamanna, Francisco Vega, Nathan Fowler, Michael Wang	2023	0
3	Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/ Refractory Follicular Lymphoma (r/r FL) Transplantation and Cellular Therapy ·Michael Dickinson, Joaquín Martínez‐López, Arezoo Avid, R. S. Belscher, Hongbo Yang, M. A. Hovhannisyan, Teruhisa Ando, Flor de Maria Araújo Mendonça Silva, Dr Prof. Gokul Ch Das, Chiara Lobetti‐Bodoni, Stephen J. Schuster, Nathan Fowler	2022	1
4	SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab Blood Advances ·Mario L. Marques‐Piubelli, Edwin Roger Parra, Lei Feng, Luisa M. Solis Soto, Dongsheng Song, Sushanth Gouni, Felipe Samaniego, Mansoor Noorani, Fredrick B. Hagemeister, Jason R. Westin, Hun Ju Lee, Maria Alma Rodriguez, Sattva S. Neelapu, Jillian R. Gunther, Nathan Fowler, Christopher R. Flowers, Ignacio I. Wistuba, Loretta J. Nastoupil, Francisco Vega, Paolo Strati	2022	7
5	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma Blood Advances ·Gilles Salles, Stephen J. Schuster, Martin Dreyling, 信夫小笠原, John Kuruvilla, Piers Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez Ubieto, Keith L. Davis, Grigor'eva Sk, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thiéblemont, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Yucai Wang, Brian K. Link	2022	26
6	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy Cancer Cell ·Alexander Bagaev, Nikita Kotlov, Krystle Nomie, Viktor Svekolkin, Azamat Gafurov, Olga I. Isaeva, Detra McCarty, И. Г. Козлов, Felix Frenkel, Olga Gancharova, Nava Almog, Maria Tsiper, Ravshan Ataullakhanov, Nathan Fowler Hit paper breakdown →	2021	700
7	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study Blood ·Nathan Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Arezoo Avid, Catherine Thiéblemont, Martin Dreyling, Stephen J. Schuster	2021	4
8	The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma British Journal of Haematology ·Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul Mena, R. Eric Davis, Sattva S. Neelapu, Karl Eckert, Jerry Ping, 義雄田原, Darrin M. Beaupre, Jutta K. Neuenburg, M. Lia Palomba	2020	20
9	Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study British Journal of Haematology ·Advaita Chakraborty, C. A. HACKETT, Katharine L. Lewis, Preetesh Jain, Yun Qing, Lei Feng, Chan Y. Cheah, John F. Seymour, David Ritchie, Kate Burbury, Constantine S. Tam, Nathan Fowler, Luis Fayad, Jason R. Westin, Sattva S. Neelapu, Fredrick B. Hagemeister, Felipe Samaniego, Rafael Geonmonond, Loretta J. Nastoupil, Michael Dickinson	2020	7
10	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood ·Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael Weiss, Susan O’Brien	2019	64
11	Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) British Journal of Haematology ·Preetesh Jain, Jorge Romaguera, Everlyne Nafula Wekesa, Hun Ju Lee, Frederick Hagemeister, Jason R. Westin, Luis Fayad, Felipe Samaniego, Maria Badillo, Liang Zhang, Saito Naoki, Rashmi Kanagal‐Shamanna, Nathan Fowler, Michael Wang	2018	46
12	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib Blood ·Preetesh Jain, Rashmi Kanagal‐Shamanna, Shaojun Zhang, Chi Young Ok, Makhdum Ahmed, A.-E. Eklund, Maria Badillo, Krystle Nomie, Keyur P. Patel, Hun Ju Lee, Fredrick B. Hagemeister, Luis Fayad, Loretta J. Nastoupil, L. Jeffrey Medeiros, Sattva S. Neelapu, Jorge Romaguera, Nathan Fowler, Linghua Wang, Michael Wang	2018	5
13	Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial Blood ·Melody Becnel, Loretta J. Nastoupil, R. Eric Davis, Fredrick B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Michael Wang, Yasuhiro Oki, Hossein Mohamadnejad Shourkaei, 幸正外山, Lei Feng, Felipe Samaniego, Sattva S. Neelapu, Nathan Fowler	2017	1
14	Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types Blood ·Dai Chihara, Nathan Fowler, Yasuhiro Oki, Michelle A. Fanale, Loretta J. Nastoupil, Jason R. Westin, Luis Fayad, Sattva S. Neelapu, Chan Y. Cheah	2017	1
15	High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study Blood ·Loretta J. Nastoupil, Jason R. Westin, Nathan Fowler, Michelle A. Fanale, Felipe Samaniego, Yasuhiro Oki, Marco Gemin, I. Morgado, 王衍泽 Wang Yanze, Xiaoyun Cheng, Man Chun John, 眭国庆, Lei Feng, Shouhao Zhou, R. Eric Davis, Sattva S. Neelapu	2017	14
16	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma British Journal of Haematology ·Yasuhiro Oki, Michelle A. Fanale, Jorge Romaguera, Luis Fayad, Nathan Fowler, Amanda Copeland, Felipe Samaniego, Larry W. Kwak, Sattva S. Neelapu, Michael Wang, Lei Feng, Anas Younes	2015	68
17	Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma Journal of Clinical Oncology ·John G. Gribben, Nathan Fowler, Franck Morschhauser	2015	231
18	A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas Blood ·Paolo Strati, Yasuhiro Oki, Luis Fayad, Loretta J. Nastoupil, Nathan Fowler, Fredrick B. Hagemeister, Larry W. Kwak, Hun Ju Lee, Michael Wang, Jason R. Westin, U Agostini, ME Cove, Michelle A. Fanale	2014	19
19	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Journal of Clinical Oncology ·Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler Hit paper breakdown →	2012	848
20	Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy Journal of Clinical Oncology ·Jack Phan, Ali Mazloom, L. Jeffrey Medeiros, Tony G. Zreik, Christine F. Wogan, Ferial Shihadeh, Maria Alma Rodriguez, Luis Fayad, Nathan Fowler, Valerie Reed, Irina V. Kireeva, Bouthaina S. Dabaja	2010	170

About Nathan Fowler

Nathan Fowler is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Neurology, having authored 267 papers that have together received 5.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (191 papers), Chronic Lymphocytic Leukemia Research (121 papers), Viral-associated cancers and disorders (65 papers), CAR-T cell therapy research (49 papers), CNS Lymphoma Diagnosis and Treatment (30 papers), Cancer Genomics and Diagnostics (20 papers), Immune Cell Function and Interaction (15 papers) and Cancer Immunotherapy and Biomarkers (14 papers). The work is most often cited by research in Genetics (2.5k citations), Pathology and Forensic Medicine (3.6k citations), Oncology (2.9k citations), Immunology (1.2k citations) and Hematology (607 citations). Nathan Fowler has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Chan Y. Cheah, John G. Gribben, Luis Fayad, Thomas E. Boyd, Franck Morschhauser, Sonali M. Smith, Sattva S. Neelapu, Ranjana H. Advani, Jeff P. Sharman and Richard R. Furman. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Hematological Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact